Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Teens are being prescribed Ozempic more than ever before — and some doctors are worried about what the trend could mean. In ...

(Corrects paragraph 3 to say 36 days, not 36 weeks) (Reuters) -Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose ...

FILE PHOTO: A person walks near the Milan Bourse (Italian stock exchange) as global markets brace for a hit to trade and ...

(Reuters) -European stocks were steady on Tuesday, shrugging off modest losses from the previous session, as investors stayed ...

European shares closed little changed on Tuesday in cautious trade as investors awaited the outcome of the second day of U.S.

Indian benchmarks traded mixed as profit booking in financial stocks countered optimism from U.S.-China trade talks and ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...